SecBot SecBot
SECBOTREPLAY Home › Report › COGT

COGT · Cogent Biosciences announced the submission of a New Drug Application…

Cogent Biosciences, Inc. · PRESS-RELEASE filed Apr 1, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 1, 2026 at 08:00 ET

Cogent Biosciences announced the submission of a New Drug Application (NDA) for bezuclastinib in second-line GIST under the FDA's RTOR program, based on positive Phase 3 PEAK trial results showing a 50% reduction in progression risk and 16.5-month median PFS. The drug combination also demonstrated a 46% objective response rate, significantly outperforming sunitinib monotherapy.

  • Submitted NDA for bezuclastinib in imatinib-resistant GIST under FDA's Real-Time Oncology Review (RTOR) program
  • Phase 3 PEAK trial showed 50% reduction in risk of progression or death (HR 0.50) vs sunitinib monotherapy
  • Median PFS of 16.5 months with bezuclastinib combination vs 9.2 months for sunitinib alone
  • Objective response rate (ORR) of 46% vs 26% in control arm

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access